Table 1 Characteristics of participants

Age (year)

44.0±9.9

52.1±8.5

<.001

Sex (%)

.879

 Male

122(61.3)

121 (62.1)

 Female

77 (38.7)

74 (37.9)

Schooling (year)

11.4±2.2

10.7±2.8

.007

Smoking (%)

.136

 Yes

85 (42.7)

69 (35.4)

 Never

114 (57.3)

126 (64.5)

Alcohol (%)

.017

 Yes

33 (16.6)

17 (8.7)

 Never

166 (83.4)

178 (91.3)

BMI status (%)

<.001

 Overweight/obese

81 (40.7)

43 (22.1)

 No

118 (59.3)

152 (77.9)

Chlorpromazine equivalent doses (mg/d)

847.6±783.8

836.1±713.8

.878

Duration of hospitalization (month)

14.2±17.0

137.0±91.0

<.001

Illness onset (year)

23.8±6.5

23.9±8.1

.075

Number of Metabolic Symptoms

1.7±1.3

0.9±1.0

<.001

Daily steps (count)

6628.1±3362.2

8278.6±3329.4

<.001

Daily steps group (%)

<.001

 ≥10000

31 (15.6)

54 (27.7)

 7500-9999

51 (25.6)

55 (28.2)

 5000-7499

50 (25.1)

55 (28.2)

 <5000

67 (33.7)

31 (15.9)

 Site 1: Attention ^a (count)

171.9±100.5

 Site 1: Processing speed ^b (score)

137.7±45.6

 Site 1: Reaction time ^c (msec)

661.8±480.3

 Site 1: Motor speed ^c (msec)

384.8±213.4

 Site 2: Attention ^d (score)

47.8±29.9

 Site 2: Processing speed ^e (score)

129.3±33.1